David Rowe - Nanoform Finland Head Manufacturing
| NANOFS Stock | SEK 17.10 1.12 6.15% |
Insider
David Rowe is Head Manufacturing of Nanoform Finland Plc
| Age | 56 |
| Phone | 358 2937 00150 |
| Web | https://www.nanoform.com |
David Rowe Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Rowe against Nanoform Finland stock is an integral part of due diligence when investing in Nanoform Finland. David Rowe insider activity provides valuable insight into whether Nanoform Finland is net buyers or sellers over its current business cycle. Note, Nanoform Finland insiders must abide by specific rules, including filing SEC forms every time they buy or sell Nanoform Finland'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Rowe over two months ago Acquisition by David Rowe of 35000 shares of Rimini Street at 1.82 subject to Rule 16b-3 | ||
David Rowe over six months ago Acquisition by David Rowe of 6666 shares of Rimini Street subject to Rule 16b-3 | ||
David Rowe over six months ago Disposition of 5088 shares by David Rowe of Rimini Street subject to Rule 16b-3 |
Nanoform Finland Management Efficiency
The company has return on total asset (ROA) of (0.1282) % which means that it has lost $0.1282 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2422) %, meaning that it generated substantial loss on money invested by shareholders. Nanoform Finland's management efficiency ratios could be used to measure how well Nanoform Finland manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Martin mark | Xbrane Biopharma AB | 43 | |
| Nina Ivers | Xbrane Biopharma AB | 53 | |
| Emanuel Bjrne | Hansa Biopharma AB | 50 | |
| Pr Lannfelt | BioArctic AB | 74 | |
| David Vikstrm | Xbrane Biopharma AB | 46 | |
| Oskar Bosson | BioArctic AB | 47 | |
| Klaus Sindahl | Hansa Biopharma AB | N/A | |
| Anne Lanner | Hansa Biopharma AB | 54 | |
| Samuel Wagner | Xbrane Biopharma AB | N/A | |
| Frida Lekander | BioArctic AB | N/A | |
| Gunilla Osswald | BioArctic AB | 62 | |
| Harald Borgeke | BioArctic AB | N/A | |
| Jan Mattsson | BioArctic AB | 63 | |
| Associate Gier | Xbrane Biopharma AB | N/A | |
| Johanna Flting | BioArctic AB | 51 | |
| Pr Gellerfors | BioArctic AB | 76 | |
| Anette Lindqvist | Xbrane Biopharma AB | 57 | |
| Katja Margell | Hansa Biopharma AB | N/A | |
| Christer Mller | BioArctic AB | 64 | |
| Erik Domines | Xbrane Biopharma AB | 59 | |
| Gunilla Andersson | BioArctic AB | 62 | |
Management Performance
| Return On Equity | -0.24 | |||
| Return On Asset | -0.13 |
Nanoform Finland Plc Leadership Team
Elected by the shareholders, the Nanoform Finland's board of directors comprises two types of representatives: Nanoform Finland inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nanoform. The board's role is to monitor Nanoform Finland's management team and ensure that shareholders' interests are well served. Nanoform Finland's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nanoform Finland's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Rowe, Head Manufacturing | ||
| Pr Haeggstrom, CoFounder CEO | ||
| Christian Jones, Chief Officer | ||
| Albert Haeggstrom, CFO Director | ||
| Henri Haartman, Director Relations | ||
| Peter Hanninen, G Counsel | ||
| Johanna MSocSc, Director HR | ||
| Niklas Sandler, Chief Officer |
Nanoform Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nanoform Finland a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.24 | |||
| Return On Asset | -0.13 | |||
| Operating Margin | (6.75) % | |||
| Current Valuation | 2.04 B | |||
| Shares Outstanding | 78.39 M | |||
| Shares Owned By Insiders | 24.75 % | |||
| Shares Owned By Institutions | 50.69 % | |||
| Price To Book | 2.84 X | |||
| Price To Sales | 912.64 X | |||
| Revenue | 1.95 M |
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Nanoform Stock
Nanoform Finland financial ratios help investors to determine whether Nanoform Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nanoform with respect to the benefits of owning Nanoform Finland security.